BACKGROUND: A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk. METHODS: We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years. RESULTS: Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1-2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4-4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence. CONCLUSIONS: Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Folsom et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: